The estimated Net Worth of Charles R Romp is at least 23.6 百万$ dollars as of 21 September 2023. Mr Romp owns over 45 units of Seagen Inc stock worth over 15,816,743$ and over the last 5 years he sold SGEN stock worth over 6,934,322$. In addition, he makes 829,160$ as Exec. VP of Commercial U.S. at Seagen Inc.
Mr has made over 26 trades of the Seagen Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 45 units of SGEN stock worth 9,293$ on 21 September 2023.
The largest trade he's ever made was selling 19,062 units of Seagen Inc stock on 2 November 2020 worth over 3,210,994$. On average, Mr trades about 2,456 units every 36 days since 2020. As of 21 September 2023 he still owns at least 69,111 units of Seagen Inc stock.
You can see the complete history of Mr Romp stock trades at the bottom of the page.
Charles R. Romp is the Exec. VP of Commercial U.S. at Seagen Inc.
As the Exec. VP of Commercial U.S. of Seagen Inc, the total compensation of Mr Romp at Seagen Inc is 829,160$. There are 9 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of 14,521,500$.
Mr Romp is 53, he's been the Exec. VP of Commercial U.S. of Seagen Inc since . There are 15 older and 4 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.
Over the last 22 years, insiders at Seagen Inc have traded over 729,924,224$ worth of Seagen Inc stock and bought 35,347,908 units worth 1,433,871,526$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Felixbaker Julian Baker Bro...、Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 18,157,295$. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth 2,262,166$.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: